Gubra
370.80 DKK
+4.33 %
Less than 1K followers
GUBRA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+4.33 %
-10.26 %
-28.35 %
-24.66 %
-5.89 %
-27.58 %
-
-
+237.09 %
Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.
Read moreMarket cap
6.06B DKK
Turnover
11.28M DKK
Revenue
2.64B
EBIT %
81.54 %
P/E
3.57
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2026-03-09
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
All
Research
Webcasts
Press releases
ShowingAll content types
Gubra – Presentation of Phase 1 Topline Results on ABBV-295 long-acting amylin analog
Gubra: ABBV-295 data doesn’t seem that far from Eli Lilly's phase 1 data on Eloralintide
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools




